Opinion|Videos|July 11, 2024
Exploring Results from CAPItello-291 Trial
William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.
Advertisement
Episodes in this series
- In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the
CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?- What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
- How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
4
Defunding Co-Payment Assistance Disrupted nAMD Care
5